If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Silvio Garattini is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Fenfluramine Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Brain Medicine & Life Sciences
Serotonin Medicine & Life Sciences
Rats Chemical Compounds
Norfenfluramine Medicine & Life Sciences
Appetite Depressants Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1952 2019

Surface Plasmon Resonance
Drug Monitoring
Anti-Idiotypic Antibodies
Antibodies
Serum

The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients

Basile, D., Parnofiello, A., Vitale, M. G., Cortiula, F., Gerratana, L., Fanotto, V., Lisanti, C., Pelizzari, G., Ongaro, E., Bartoletti, M., Garattini, S. K., Andreotti, V. J., Bacco, A., Iacono, D., Bonotto, M., Casagrande, M., Ermacora, P., Puglisi, F., Pella, N., Fasola, G. & 2 others, Aprile, G. & Cardellino, G. G., Apr 2019, In : Journal of Cachexia, Sarcopenia and Muscle. 10, 2, p. 368-377 10 p.

Research output: Contribution to journalArticle

Open Access
Pancreatic Neoplasms
Skeletal Muscle
Sarcopenia
Confidence Intervals
Disease-Free Survival

The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients

Basile, D., Parnofiello, A., Vitale, M. G., Cortiula, F., Gerratana, L., Fanotto, V., Lisanti, C., Pelizzari, G., Ongaro, E., Bartoletti, M., Garattini, S. K., Andreotti, V. J., Bacco, A., Iacono, D., Bonotto, M., Casagrande, M., Ermacora, P., Puglisi, F., Pella, N., Fasola, G. & 2 others, Aprile, G. & Cardellino, G. G., Apr 2019, In : Journal of Cachexia, Sarcopenia and Muscle. 10, 2, p. 368-377 10 p.

Research output: Contribution to journalArticle

Open Access
Pancreatic Neoplasms
Skeletal Muscle
Sarcopenia
Confidence Intervals
Disease-Free Survival
Pulmonary Hypertension
Pharmaceutical Preparations
Meta-Analysis
Marketing
Therapeutics

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

Pusceddu, S., Vernieri, C., Di Maio, M., Marconcini, R., Spada, F., Massironi, S., Ibrahim, T., Brizzi, M. P., Campana, D., Faggiano, A., Giuffrida, D., Rinzivillo, M., Cingarlini, S., Aroldi, F., Antonuzzo, L., Berardi, R., Catena, L., De Divitiis, C., Ermacora, P., Perfetti, V. & 32 others, Fontana, A., Razzore, P., Carnaghi, C., Davì, M. V., Cauchi, C., Duro, M., Ricci, S., Fazio, N., Cavalcoli, F., Bongiovanni, A., La Salvia, A., Brighi, N., Colao, A., Puliafito, I., Panzuto, F., Ortolani, S., Zaniboni, A., Di Costanzo, F., Torniai, M., Bajetta, E., Tafuto, S., Garattini, S. K., Femia, D., Prinzi, N., Concas, L., Lo Russo, G., Milione, M., Giacomelli, L., Buzzoni, R., Delle Fave, G., Mazzaferro, V. & de Braud, F., Aug 2018, In : Gastroenterology. 155, 2, p. 479-489.e7

Research output: Contribution to journalArticle

Neuroendocrine Tumors
Metformin
Somatostatin
Disease-Free Survival
Everolimus